Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLB1 | P16278 | 1/20 | 0.48 |
| ▸ | GBA1 | P04062 | 3/20 | 0.43 |
| ▸ | GUSB | P08236 | 2/20 | 0.41 |
| ▸ | EBP | Q15125 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23379171 | 0.87 | GBA1 (0.37) | GLB1GBA1GUSBEBPSIGMAR1 | |
| SCHEMBL22778679 | 0.78 | GLB1 (0.52) | GLB1GBA1GUSBEBPSIGMAR1 | |
| SCHEMBL20244726 | 0.78 | GLB1 (0.52) | GLB1GBA1GUSBEBPSIGMAR1 | |
| SCHEMBL12524320 | 0.78 | ATM (0.35) | — | |
| SCHEMBL22991850 | 0.76 | GLB1 (0.54) | GLB1GBA1GUSBEBPSIGMAR1 | |
| SCHEMBL24882683 | 0.76 | GLB1 (0.54) | GLB1GBA1GUSBEBPSIGMAR1 | |
| SCHEMBL24090559 | 0.76 | GLB1 (0.54) | GLB1GBA1GUSBEBPSIGMAR1 | |
| SCHEMBL23767404 | 0.75 | GUSB (0.59) | GLB1GBA1GUSBEBPSIGMAR1 | |
| SCHEMBL16241085 | 0.73 | CACNA1H (0.43) | — | |
| SCHEMBL21701406 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10865216-B2 | Tricyclic Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865216-B2 | Tricyclic Gyrase inhibitors | TOP1, TOP2A, TOP2B | GLB1 189/4885GBA1 715/4885GUSB 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.